- Home
- LPSN vs ICCC Comparison
LPSN vs ICCC Comparison
Compare LPSN & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPSN
- ICCC
- Stock Information
- Founded
- LPSN 1995
- ICCC 1982
- Country
- LPSN United States
- ICCC United States
- Employees
- LPSN N/A
- ICCC N/A
- Industry
- LPSN EDP Services
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- LPSN Technology
- ICCC Health Care
- Exchange
- LPSN Nasdaq
- ICCC Nasdaq
- Market Cap
- LPSN 72.8M
- ICCC 60.1M
- IPO Year
- LPSN 2000
- ICCC 1987
- Fundamental
- Price
- LPSN $0.97
- ICCC $6.62
- Analyst Decision
- LPSN Hold
- ICCC
- Analyst Count
- LPSN 3
- ICCC 0
- Target Price
- LPSN $1.20
- ICCC N/A
- AVG Volume (30 Days)
- LPSN 1.2M
- ICCC 42.4K
- Earning Date
- LPSN 07-30-2025
- ICCC 08-12-2025
- Dividend Yield
- LPSN N/A
- ICCC N/A
- EPS Growth
- LPSN N/A
- ICCC N/A
- EPS
- LPSN N/A
- ICCC N/A
- Revenue
- LPSN $292,025,000.00
- ICCC $27,302,766.00
- Revenue This Year
- LPSN N/A
- ICCC N/A
- Revenue Next Year
- LPSN $0.82
- ICCC N/A
- P/E Ratio
- LPSN N/A
- ICCC N/A
- Revenue Growth
- LPSN N/A
- ICCC 28.29
- 52 Week Low
- LPSN $0.57
- ICCC $3.34
- 52 Week High
- LPSN $2.08
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- LPSN 66.22
- ICCC 52.40
- Support Level
- LPSN $0.88
- ICCC $5.63
- Resistance Level
- LPSN $1.04
- ICCC $7.14
- Average True Range (ATR)
- LPSN 0.07
- ICCC 0.60
- MACD
- LPSN 0.03
- ICCC -0.02
- Stochastic Oscillator
- LPSN 83.58
- ICCC 53.11
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.